Read the anns 06/12/23
This trial is not sponsored by IMU and not under IMU's control. The Uni London has chosen PD1-Vaxx over Keytruda. Could be because of costs or, as they said, the superior properties of PD1-Vaxx.
Again, market gives a damn, but the scientists approve it.
Investors follow the sp, scientists follow the science. Who will get it right in the end?
GLTA
Read the anns 06/12/23This trial is not sponsored by IMU and not...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.003(5.26%) |
Mkt cap ! $395.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.7¢ | 5.4¢ | $1.444M | 26.24M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 3824179 | 5.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.5¢ | 172983 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |